609 related articles for article (PubMed ID: 18501499)
1. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment on: Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial CEFUB).
van der Poel HG
Eur Urol; 2009 Mar; 55(3):667-8. PubMed ID: 18501500
[No Abstract] [Full Text] [Related]
3. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
4. Detection of tumours of the urinary tract in voided urine.
Zwarthoff EC
Scand J Urol Nephrol Suppl; 2008 Sep; (218):147-53. PubMed ID: 18815929
[TBL] [Abstract][Full Text] [Related]
5. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
[TBL] [Abstract][Full Text] [Related]
6. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
7. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
8. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
9. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
10. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.
Rouprêt M; Hupertan V; Yates DR; Comperat E; Catto JW; Meuth M; Lackmichi A; Ricci S; Lacave R; Gattegno B; Richard F; Hamdy FC; Cussenot O
BJU Int; 2008 Jun; 101(11):1448-53. PubMed ID: 18325051
[TBL] [Abstract][Full Text] [Related]
12. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
13. Detection of bladder cancer by semi-automated microsatellite analysis of urine sediment.
Baron A; Mastroeni F; Moore PS; Bonetti F; Orlandini S; Manfrin E; Schiavone D; Migliorini F; Lusuardi L; Mobilio G; Scarpa A
Adv Clin Path; 2000 Jan; 4(1):19-24. PubMed ID: 10936895
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
15. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
[TBL] [Abstract][Full Text] [Related]
16. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
17. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
18. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.
van Rhijn BW; Lurkin I; Chopin DK; Kirkels WJ; Thiery JP; van der Kwast TH; Radvanyi F; Zwarthoff EC
Clin Cancer Res; 2003 Jan; 9(1):257-63. PubMed ID: 12538478
[TBL] [Abstract][Full Text] [Related]
19. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
van der Aa MN; Steyerberg EW; Bangma C; van Rhijn BW; Zwarthoff EC; van der Kwast TH
J Urol; 2010 Jan; 183(1):76-80. PubMed ID: 19913254
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]